This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           July 29, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

WHO: Risk of certain cancers is higher in transgender communities
QUARTZ
A July 2015 report published by the World Health Organization (WHO) highlights distinct health risks for the world’s transgender community. Of particular note is the measurably higher risk of cervical, ovarian, and uterine cancer faced by transgender men who retain genitalia they were born with. Due to stigma and social exclusion, many do not regularly receive gynecological examinations and concomitant cervical and ovarian screenings.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




SGO NEWS


Annual Meeting Call for Abstracts and Surgical Films open July 20-Sept. 15
The Call for Abstracts and Surgical Films for the 2016 SGO Annual Meeting on Women’s Cancer is now open and closes at 11:59 p.m. CT Tuesday, Sept. 15. The 47th Annual Meeting will take place March 19-22, 2016, at the San Diego Convention Center in San Diego, CA.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


OVARIAN CANCER


Younger women may face worse ovarian cancer outcomes after primary therapy
Gynecologic Cancer Advisor
Upon completion of primary therapy, women with low-grade serous carcinoma of the ovary (LGSOC) or peritoneum (LGSPC) who are under the age of 35 and have persistent disease face worse outcomes, according to a recent study published online ahead of print in the Journal of Clinical Oncology. “LGSOC or LGSPC is a rare subtype of ovarian or peritoneal cancer characterized by young age at diagnosis and relative resistance to chemotherapy,” the authors noted. They hoped to validate these findings in the current study.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
SPONSORED CONTENT


Important new target identified for ovarian cancer therapy
News-Medical
Scientists at Lawson Health Research Institute have uncovered an important new target for ovarian cancer therapy. Contrary to current research this new study found that LKB1, a molecule that regulates the metabolism of many adult cells, is an important molecule in the cancer's promotion and survival. Thousands of women are living with ovarian cancer in Canada. It is estimated that this year, 2,800 Canadian women will be newly diagnosed with this disease.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Protein imbalances within cells can cause ovarian cancer
News-Medical
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found. The discovery is a major breakthrough because, until now, genetic aberrations have been seen as the main cause of almost all cancer. The research, published in the journal Oncogene, demonstrates that protein imbalance is a powerful prognostic tool, indicating whether or not patients are likely to respond to chemotherapy and whether a tumor is likely to spread to other sites.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


GENETICS


Management of patients with a genetic variant of unknown significance
Medscape (Free login required)
Genetic testing that results in a variant of unknown significance can be confusing and stressful for patients and healthcare providers. The very real possibility of a variant of unknown significance should be discussed in pretest counseling, and patients should be informed that if a variant of unknown significance is identified, recommendations will be based on personal and family history. Other at-risk family members will not be offered testing outside of a reclassification research effort.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


HEALTH POLICY


Doctors object to high cancer-drug prices
The Wall Street Journal (Subscription required)
More than 100 oncologists from top cancer hospitals around the U.S. have issued a harsh rebuke over soaring cancer-drug prices and called for new regulations to control them, according to an editorial published in the Mayo Clinic’s Proceedings. The physicians are the latest in a growing roster of objectors to drug prices. Critics from doctors to insurers to state Medicaid officials have voiced alarm about prescription drug prices, which rose more than 12 percent last year in the U.S., the biggest annual increase in a decade, according to the nation’s largest pharmacy-benefit manager.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  Ovarian cancer updates from ASCO 2015:

Four prominent experts in ovarian cancer met in Chicago to provide perspectives related to progress made toward personalized therapy. More
 


MISSED AN ISSUE OF WOMEN'S CANCER NEWS?
Visit the SGO Women's Cancer News archive page.


FDA mulls expansion of diagnostic test oversight
MedPage Today
At a time when physicians are complaining about the coming "tsunami" of regulations they'll have to follow for quality reporting and electronic health records, federal officials are considering increasing regulations in another area: laboratory-developed tests. LDTs, as they are known, refer to tests that are developed and used only at a specific laboratory — for example, a test for erythrocyte sedimentation rate that a hospital lab might use. And in a growing number of cases, LDT's also involve genetic tests that purport to predict, say, a woman's risk of getting breast or ovarian cancer — tests that are used only by the company marketing them and that are not sent out to independent labs or consumers as test kits.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


CHEMOTHERAPY


What if chemo doesn't help you live longer or better?
NPR
Chemotherapy given to patients at the end of life often does more harm than good, according to a study that calls into question this common practice. We're not talking here about standard chemotherapy, which can be used to greatly prolong life and sometimes cure cancer. Instead, the study published online, in the medical journal JAMA Oncology, focuses on chemotherapy given to people with solid tumors who have been diagnosed with terminal disease and aren't expected to live more than six months.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




BREAST CANCER


Aromatase inhibitors 'significantly reduce breast cancer deaths'
Medical News Today
A new study published in The Lancet claims a class of hormonal drugs called aromatase inhibitors may significantly reduce the risk of death among postmenopausal women with estrogen receptor-positive breast cancer - the most common form of the disease.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

July 22, 2015
July 15, 2015
July 8, 2015
July 1, 2015






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063